Marisa J. Canale, PA

Marisa Canale practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Marisa Canale's NPI, 1598483935, was assigned on August 22, 2022.

Marisa Canale's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Marisa Canale's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Marisa Canale to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Marisa Canale practices, 2 sites in all. Vendor and product names are available with a free account.

Medical is Marisa Canale's primary specialty in the NPI Registry, under taxonomy code 363AM0700X.

CMS data shows 161 Medicare services from Marisa Canale across 3 procedure codes in 2024, for 69 Medicare patients. Medicare paid $9,333 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 69 Medicare patients who saw Marisa Canale in 2024. The largest group is 65 to 74, with 35 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 3.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Marisa Canale's median patient age at 71, with 48% women.

In 2024, Marisa Canale wrote 133 Medicare Part D claims for 45 patients. 91% of them were for generic drugs. CMS names the drug for 16 of them, across 1 drug with 11 or more claims each, at $134 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Marisa Canale for performance year 2024, reported as part of a group. Marisa Canale accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Marisa Canale as offering telehealth.

CMS Open Payments shows 1 general payment to Marisa Canale from 1 drug or device company in 2024. Food and beverage make up the largest share, 100% of the total. BTG International, Inc. paid the most, $100.